|
November 2, 2006
Tramiprosate (Alzhemed™) Phase II clinical results published in Neurology
Tramiprosate (ALZHEMED™) Currently in Large Phase III Clinical Trials in North America and Europe
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that Neurology, a worldwide, leading, peer-reviewed,
medical journal in the field of neurology, has published today an online version of a publication on the Phase II clinical
trial of tramiprosate (3-amino-1-propanesulfonic acid (3APS); ALZHEMED™) conducted in mild-to-moderate Alzheimer's
disease (AD) patients. Tramiprosate (ALZHEMED™) represents a potential new class of disease-modifying agents and is
Neurochem's investigational product candidate for the treatment of Alzheimer's disease. The results reported in the paper
demonstrate that long-term administration of tramiprosate (ALZHEMED™) is safe, tolerated and reduces the level of
amyloid ß42 (Aß42) in the cerebrospinal fluid (CSF) of AD patients. In addition, mean ADAS-cog1 and
MMSE2 scores remained near baseline levels in the mild AD group over the 20 months of follow-up.
The print issue of the publication will be available in the November 28, 2006 issue of Neurology. The article entitled
"A phase II study targeting amyloid ß with 3APS in mild-to-moderate Alzheimer disease" will be
highlighted in the "In This Issue" section of the journal. An electronic version of the article is already
accessible online, and can be found at
http://www.neurology.org
under the "Expedited E-pub" section.
"This paper demonstrates the potential benefits of ALZHEMED™," said Dr. Paul S. Aisen, M.D., Professor of
Neurology and Medicine at Georgetown University Medical Center, and principal investigator in the United States of the
ongoing Phase III clinical trial for tramiprosate (ALZHEMED™). "The ALZHEMED™ program is at the forefront
of therapeutic research in AD. The Phase II results show that ALZHEMED™ enters the central nervous system, where it
reduces levels of Aß. We look forward to concluding the ongoing North American Phase III clinical trial in January
2007, with the hope of introducing a new therapeutic avenue for patients, and slowing the progression of the disease,"
he concluded.
This Phase II clinical trial sought to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of
tramiprosate (ALZHEMED™) in patients with mild-to-moderate AD using a three-month, double-blind, randomized, and
parallel group trial design. Patients who completed the Phase II trial were then eligible to receive tramiprosate
(ALZHEMED™) in a follow-on open-label study.
Findings about tramiprosate (ALZHEMED™) reported in the article include:
-
Tramiprosate (ALZHEMED™) had no significant impact on vital signs and laboratory test values. The most
frequent side effects were nausea, vomiting and diarrhea, which were intermittent and mild-to-moderate in severity.
-
Tramiprosate (ALZHEMED™) crossed the blood-brain-barrier, and dose-dependently reduced CSF Aß42 levels
after three months of treatment. Results on psychometric measures showed no differences between groups over the
three-month double-blind period, consistent with the proposed mechanism of action of tramiprosate
(ALZHEMED™) which is not expected to confer short-term symptomatic benefits.
-
There was a gradual decline in the psychometric scores for subjects remaining in the study over the course of the
cumulative 20-month follow-up period. By 20 months, the mean [SEM3] change from baseline in psychometric
scores for the mild and moderate groups were the following: ADAS-cog: mild, 3.1 [2.3], moderate, 12.7 [2.6];
CDR-SB4, mild 2.3 [0.9], moderate 2.8 [0.8].
About Tramiprosate (ALZHEMED™)
Tramiprosate (ALZHEMED™) is a small, orally-administered molecule known as an amyloid ß antagonist, which
crosses the blood-brain-barrier, binds to soluble Aß peptide and interferes with the amyloid cascade that is
associated with amyloid deposition and the toxic effects of Aß peptide in the brain. The presence of amyloid in
the brain is one of the major histopathological characteristics of AD. The amyloid cascade hypothesis proposes that
certain forms of Aß peptide are toxic and causally related to the severity of AD. The Aß peptide is one of
the most promising targets for the development of AD therapies.
About the Phase III Clinical Trials for Tramiprosate (ALZHEMED™)
Neurochem is currently conducting a multi-center, randomized, double-blind, placebo-controlled and parallel-designed,
18-month Phase III clinical trial in 1,052 mild-to-moderate AD patients, which is being carried out at close to 70
clinical sites across the United States and Canada. The trial is scheduled to be completed in January 2007. All patients
who complete the North American Phase III clinical trial are eligible to receive tramiprosate
(ALZHEMED™) in an open-label extension study.
Neurochem is also actively advancing an 18-month Phase III clinical trial for tramiprosate (ALZHEMED™) in Europe, which
was initiated in September 2005. The ongoing European Phase III clinical trial, an international, multi-center, randomized,
double-blind, placebo-controlled and parallel-designed study, is progressing on schedule and is designed to investigate
the safety, efficacy and disease-modifying potential of tramiprosate (ALZHEMED™). Some 930 mild-to-moderate AD patients
are expected to take part and enrollment is expected to be completed in fall 2006.
About Alzheimer's Disease
Alzheimer's disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a person's
cognitive and motor functions, their activities of daily living, alters their behavior and gradually destroys the
brain.
AD is the most common cause of dementia in our aging population. Almost five million individuals in the United States
alone currently suffer from the condition. The U.S. Alzheimer's Association estimates that by the year 2025, over 22
million people worldwide will be afflicted.
According to a report commissioned by the U.S. Alzheimer's Association, AD costs American businesses approximately US$61
billion a year. That price tag includes US$24.6 billion for direct health care of Alzheimer's patients and US$36.5
billion to cover costs related to caregivers of AD patients, including lost productivity, absenteeism and worker
replacement.
About Neurochem
Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet
medical needs. Eprodisate (KIACTA™; formerly FIBRILLEX™) is currently being developed for the treatment of AA
amyloidosis, and is under regulatory review for marketing approval by the U.S. Food and Drug Administration and European
Medicines Agency. Tramiprosate (ALZHEMED™), for the treatment of Alzheimer's disease, is currently in Phase III
clinical trials in both North America and Europe and tramiprosate (CEREBRIL™), for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
1- Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog). The ADAS-cog is a 70-point scale designed to
measure, with the use of questionnaires, the progression and the severity of cognitive decline as seen in AD. The
ADAS-cog scale quantifies the number of wrong answers. Consequently, a high score on the scale indicates a more severe
case of cognitive decline. When analyzing results, a negative score indicates the improvement of cognitive function
and a positive score the deterioration of such function. The ADAS-cog has been validated by the regulatory authorities
as the gold standard scale for the monitoring of cognitive function in AD patients. This scale is a compulsory parameter
of efficacy when submitting an AD drug for market approval to the authorities such as the U.S. Food and Drug
Administration.
2- Mini-Mental State Examination (MMSE) is a standard mental status exam routinely used to measure a person's basic
cognitive skills, such as short-term memory, long-term memory, orientation, writing and language. If every answer is
correct, a maximum score of 30 points is possible.
3- Standard Error of Mean (SEM).
4- Clinical Dementia Rating - sum of boxes rating scale (CDR-SB), a measure of global performance.
This news release contains forward-looking statements regarding tramiprosate (ALZHEMED™) as well as regarding
continuing and further development efforts. These statements are based on the current analysis and expectations of
management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results
to differ materially from this current analysis and these expectations. Analysis regarding the results of clinical
trials may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the
endpoints sought in the clinical trials were met (which is not certain), there is no certainty that regulators would
ultimately approve tramiprosate (ALZHEMED™) for sale to the public. Risks and uncertainties may include: failure
to demonstrate the safety, tolerability and efficacy of our product, the expense and uncertainty of obtaining regulatory
approval, including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even
if regulatory approval is obtained, therapeutic products are generally subject to: stringent on-going governmental
regulation, challenges in gaining market acceptance, and competition. Neurochem does not undertake any obligation
to publicly update its forward-looking statements, whether as a result of new information, future events, or otherwise.
Please see the Annual Information Form for further risk factors that might affect the Company and its business.
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
|
